N-terminal mono-PEGylation of growth hormone antagonist: Correlation of PEG size and pharmacodynamic behavior

International Journal of Pharmaceutics

Volumn 453, Issue 2, 2013, Pages 533-540

  Wu, Ling ^a,c   Ho, Sa V ^b   Wang, Wei ^b   Gao, Jianping ^a   Zhang, Guifeng ^a   Su, Zhiguo ^a   Hu, Tao ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Acromegaly; Growth hormone antagonist; N terminus; PEGylation; Polyethylene glycol

Indexed keywords

GROWTH HORMONE ANTAGONIST; HORMONE ANTAGONIST; MACROGOL; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL ACTIVITY; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG CONJUGATION; FLUORESCENCE ANALYSIS; HORMONE ACTION; LIGHT SCATTERING; MALE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; RAT; SEDIMENTATION RATE; ULTRACENTRIFUGATION;

EID: 84884153916     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.06.022     Document Type: Article

References (41)

1. Bailon, P., Palleroni, A., Schaffer, C.A., Spence, C.L., Fung, W.J., Porter, J.E., Ehrlich, G.K., Pan, W., Xu, Z.X., Modi, M.W., Farid, A., Berthold, W., 2001. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycolconjugated interferon α-2a for the treatment of hepatitis C. Bioconjugate Chem. 12, 195-202. (Pubitemid 32235471)
2. Bergamaschi, S., Ronchi, C.L., Giavoli, C., Ferrante, E., Verrua, E., Ferrari, D.I., Lania, A., Rusconi, R., Spada, A., Beck-Peccoz, P., 2010. Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy. Horm. Res. Paediatr. 73, 74-79.
3. Cunningham, B.C., Ultsch, M., de Vos, A.M., Mulkerrin, M.G., Clauser, K.R., Wells, J.A., 1991. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254, 821-825. (Pubitemid 21917402)
4. Dhalluin, C., Ross, A., Leuthold, L.A., Foser, S., Gsell, B., Muller, F., Senn, H., 2005a. Structural and biophysical characterization of the 40 kDa PEG-interferon alpha2a and its individual positional isomers. Bioconjugate Chem. 16, 504-517. (Pubitemid 40696041)
5. Dhalluin, C., Ross, A., Huber, W., Gerber, P., Brugger, D., Gsell, B., Senn, H., 2005b. Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-α2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjugate Chem. 16, 518-527. (Pubitemid 40696042)
6. Doherty, D.H., Rosendahl, M.S., Smith, D.J., Hughes, J.M., Chlipala, E.A., Cox, G.N., 2005. Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor. Bioconjugate Chem. 16, 1291-1298. (Pubitemid 41368133)
7. Florini, J.R., Ewton, D.Z., Coolican, A.S., 1996. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr. Rev. 17, 481-517. (Pubitemid 26346639)
8. Goffin, V., Touraine, P., 2002. Pegvisomant. Pharmacia. Curr. Opin. Investig. Drugs 3, 752-757.
9. González-González, M., Mayolo-Deloisa, K., Rito-Palomares, M., 2012. PEGylation, detection and chromatographic purification of site-specific PEGylated CD133-Biotin antibody in route to stem cell separation. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 893-894, 182-186.
10. Higham, C.E., Trainer, P.J., 2008. Growth hormone excess and the development of growth hormone receptor antagonists. Exp. Physiol. 93, 1157-1169.
11. Higham, C.E., Chung, T.T., Lawrance, J., Drake, W.M., Trainer, P.J., 2009. Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin. Endocrinol. 71, 86-91.
12. Hu, T., Acharya, S.A., Manjula, B.N., 2005. Influence of the chemistry of conjugation of poly(ethylene glycol) to Hb on the oxygen-binding and solution properties of the PEG-Hb conjugate. Biochem. J. 392, 555-564. (Pubitemid 43022735)
13. Hu, T., Manjula, B.N., Li, D., Brenowitz, M., Acharya, A.S., 2007. Influence of intramolecular cross-links on the molecular, structural and functional properties of PEGylated hemoglobin. Biochem. J. 402, 143-151.
14. Hu, T., Li, D., Manjula, B.N., Brenowitz, M., Prabhakaran, M., Acharya, A.S., 2009. PEGylation of Val-1(α) destabilizes the tetrameric structure of hemoglobin. Biochemistry 48, 608-616.
15. Hu, T., Li, D., Meng, F., Prabhakaran, M., Acharya, S.A., 2011. Increased inter dimeric interaction of oxy hemoglobin is necessary for attenuation of reductive pegylation promoted dissociation of tetramer. Art. Cells Blood Sub. Biotechnol. 39, 69-78.
16. Hu, T., Li, D., Wang, J., Wang, Q., Liang, Y., Su, Y., Ma, G., Su, Z., Wang, S., 2012. Propylbenzmethylation at Val-1(α) markedly increases the tetramer stability of the PEGylated hemoglobin: a comparison with propylation at Val-1(α). Biochim. Biophys. Acta 1820, 2044-2051.
17. Jevsevar, S., Kunstelj, M., Porekar, V.G., 2010. PEGylation of therapeutic proteins. Biotechnol. J. 5, 113-128.
18. Kopchick, J.J., Parkinson, C., Stevens, E.C., Trainer, P.J., 2002. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr. Rev. 23, 623-646. (Pubitemid 35191626)
19. Li, C., Lin, Q., Wang, J., Ma, G., Su, Z., Hu, T., 2012. Preparation, structural analysis and bioactivity of ribonuclease A-albumin conjugate: tetra-conjugation or PEG as the linker. J. Biotechnol. 162, 283-288.
20. Liu, S., Sun, L., Wang, J., Ma, G., Su, Z., Hu, T., 2012a. Mono-PEGylation of ribonuclease A: high PEGylation efficiency by thiolation with small molecular weight reagent. Process Biochem. 47, 1364-1370.
21. Liu, R., Li, D., Wang, J., Qiu, R., Lin, Q., Zhang, G., Ma, G., Su, Z., Hu, T., 2012b. Preparation, characterization and in vitro bioactivity of N-terminally PEGylated staphylokinase dimers. Process Biochem. 47, 41-46.
22. Mayolo-Deloisa, K., Lienqueo, M.E., Andrews, B., Rito-Palomares, M., Asenjo, J.A., 2012. Hydrophobic interaction chromatography for purification of monoPEGylated RNase A. J. Chromatogr. A 1242, 11-16.
23. Mosharraf, M., Malmberg, M., Fransson, J., 2007. Formulation, lyophilization and solid-state properties of a pegylated protein. Int. J. Pharm. 336, 215-232. (Pubitemid 46680493)
24. Neggers, S.J., van der Lely, A.J., 2011. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm. IGF Res. 21, 129-133.
25. Nie, Y., Zhang, X., Wang, X., Chen, J., 2006. Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin. Bioconjugate Chem. 17, 995-999. (Pubitemid 44162618)
26. Pabst, T.M., Buckley, J.J., Ramasubramanyan, N., Hunter, A.K., 2007. Comparison of strong anion-exchangers for the purification of a PEGylated protein. J. Chromatogr. A 1147, 172-182. (Pubitemid 46466833)
27. Pai, S.S., Hammouda, B., Hong, K., Pozzo, D.C., Przybycien, T.M., Tilton, R.D., 2011. The conformation of the poly(ethylene glycol) chain in mono-PEGylated lysozyme and mono-PEGylated human growth hormone. Bioconjugate Chem. 22, 2317-2323.
28. Perkins, S.J., 2001. X-ray and neutron scattering analyses of hydration shells: a molecular interpretation based on sequence predictions and modelling fits. Biophys. Chem. 93, 129-139. (Pubitemid 34142182)
29. Porekar, V.G., Zore, I., Podobnik, B., Menart, V., 2008. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr. Opin. Drug Discov. Dev. 11, 242-250. (Pubitemid 351281064)
30. Reichel, C., 2012. SARCOSYL-PAGE: a new electrophoretic method for the separation and immunological detection of PEGylated proteins. Methods Mol. Biol. 869, 65-79.
31. Ross, R.J.M., Leung, K.C., Maamra, M., Bennett, W., Doyle, N., Waters, M.J., Ho, K.K.Y., 2001. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimmer. J. Clin. Endocrinol. Metab. 86, 1716-1723. (Pubitemid 32374928)
32. Sherlock, M., Woods, C., Sheppard, M.C., 2011. Medical therapy in acromegaly. Nat. Rev. Endocrinol. 7, 291-300.
33. Stafford, W.F., Braswell, E.H., 2004. Sedimentation velocity, multi-speed method for analyzing polydisperse solutions. Biophys. Chem. 108, 273-279. (Pubitemid 38388494)
34. Tang, L., Jariwala, F., Bolgar, M., Lloyd, D.K., 2012. Separation and detection of bismaleimide- polyethylene glycol and mono-maleimide-polyethylene glycol by reversed-phase high pressure liquid chromatography. J. Chromatogr. A 1246, 117-122.
35. Thorner, M.O., Strasburger, C.J., Wu, Z., Straume, M., Bidlingmaier, M., Pezzoli, S.S., Zib, K., Scarlett, J.C., Bennett, W.F., 1999. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J. Clin. Endocrinol. Metab. 84, 2098-2103. (Pubitemid 30647040)
36. Veldhuis, J.D., Bidlingmaier, M., Anderson, S.M., Evans, W.S., Wu, Z., Strasburger, C.J., 2002. Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. J. Clin. Endocrinol. Metab. 87, 5737-5745. (Pubitemid 36034384)
37. Veronese, F.M., 2001. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22, 405-417. (Pubitemid 32007845)
38. Veronese, F.M., Pasut, G., 2005. PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451-1458. (Pubitemid 41483874)
39. Wang, J., Hu, T., Liu, Y., Ma, G., Su, Z., 2011. Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase. Anal. Biochem. 412, 114-116.
40. Wang, Y., Liu, Y., Chen, J., Hao, S., Hu, T., Ma, G., Su, Z., 2010. Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli. Int. J. Pharm. 386, 156-164.
41. Wattendorf, U., Merkle, H.P., 2008. PEGylation as a tool for the biomedical engineering of surface modified microparticles. J. Pharm. Sci. 97, 4655-4669.